NYSE:HAE - Haemonetics Stock Price, Price Target & More

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics declared that its board has approved a share repurchase program on Tuesday, February 6th 2018, which authorizes the company to repurchase $260,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Haemonetics (NYSE:HAE) posted its quarterly earnings results on Tuesday, May, 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.43. The medical instruments supplier had revenue of $233.55 million for the quarter, compared to analyst estimates of $226.63 million. Haemonetics had a net margin of 5.04% and a return on equity of 12.71%. Haemonetics's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.39 earnings per share. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Haemonetics.

Haemonetics issued an update on its FY19 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $2.00-2.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.09.

6 equities research analysts have issued 1 year price objectives for Haemonetics' shares. Their forecasts range from $50.00 to $100.00. On average, they expect Haemonetics' share price to reach $81.40 in the next twelve months. View Analyst Ratings for Haemonetics.

Haemonetics saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 884,267 shares, a decline of 32.0% from the March 30th total of 1,300,931 shares. Based on an average daily volume of 435,043 shares, the short-interest ratio is presently 2.0 days. Approximately 1.7% of the shares of the company are sold short.

Some companies that are related to Haemonetics include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD), Globus Medical (GMED), NovoCure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).

Media stories about HAE stock have been trending positive this week, according to Accern. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Haemonetics earned a media sentiment score of 0.42 on Accern's scale. They also assigned news headlines about the medical instruments supplier an impact score of 46.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Haemonetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.96%), Wells Fargo & Company MN (3.58%), Neuberger Berman Group LLC (3.25%), Dimensional Fund Advisors LP (2.90%), Victory Capital Management Inc. (2.82%) and Millennium Management LLC (2.21%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., Neuberger Berman Group LLC, Wells Fargo & Company MN, Segall Bryant & Hamill LLC, WINTON GROUP Ltd, Royal Bank of Canada and Schwab Charles Investment Management Inc.. Company insiders that have sold Haemonetics company stock in the last year include Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Susan Bartlett Foote and Willaim P Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Columbus Circle Investors, OppenheimerFunds Inc., Federated Investors Inc. PA, Picton Mahoney Asset Management and Allianz Asset Management GmbH. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $90.66.

Haemonetics has a market capitalization of $4.73 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]